- Home
- CTXR vs BOWN Comparison
CTXR vs BOWN Comparison
Compare CTXR & BOWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTXR
- BOWN
- Stock Information
- Founded
- CTXR 2007
- BOWN 2023
- Country
- CTXR United States
- BOWN United States
- Employees
- CTXR N/A
- BOWN N/A
- Industry
- CTXR Biotechnology: Pharmaceutical Preparations
- BOWN
- Sector
- CTXR Health Care
- BOWN
- Exchange
- CTXR Nasdaq
- BOWN Nasdaq
- Market Cap
- CTXR 84.9M
- BOWN 100.3M
- IPO Year
- CTXR N/A
- BOWN 2023
- Fundamental
- Price
- CTXR $2.65
- BOWN $10.92
- Analyst Decision
- CTXR Buy
- BOWN
- Analyst Count
- CTXR 2
- BOWN 0
- Target Price
- CTXR $100.00
- BOWN N/A
- AVG Volume (30 Days)
- CTXR 561.0K
- BOWN 39.8K
- Earning Date
- CTXR 02-12-2025
- BOWN 01-01-0001
- Dividend Yield
- CTXR N/A
- BOWN N/A
- EPS Growth
- CTXR N/A
- BOWN N/A
- EPS
- CTXR N/A
- BOWN 0.39
- Revenue
- CTXR N/A
- BOWN N/A
- Revenue This Year
- CTXR N/A
- BOWN N/A
- Revenue Next Year
- CTXR N/A
- BOWN N/A
- P/E Ratio
- CTXR N/A
- BOWN $28.26
- Revenue Growth
- CTXR N/A
- BOWN N/A
- 52 Week Low
- CTXR $2.44
- BOWN $10.31
- 52 Week High
- CTXR $26.75
- BOWN $10.98
- Technical
- Relative Strength Index (RSI)
- CTXR 30.59
- BOWN 53.16
- Support Level
- CTXR $2.44
- BOWN $10.93
- Resistance Level
- CTXR $2.85
- BOWN $10.97
- Average True Range (ATR)
- CTXR 0.34
- BOWN 0.02
- MACD
- CTXR 0.15
- BOWN -0.00
- Stochastic Oscillator
- CTXR 24.99
- BOWN 25.13
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
About BOWN Bowen Acquisition Corp
Bowen Acquisition Corp is a blank check company.